 Youping Deng
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computational Biology | 6 | 2015 | 30 | 1.510 |
Why?
| | Genomics | 4 | 2015 | 51 | 1.010 |
Why?
| | Breast Neoplasms | 5 | 2022 | 435 | 0.960 |
Why?
| | DNA Methylation | 2 | 2015 | 169 | 0.910 |
Why?
| | Gene Regulatory Networks | 4 | 2014 | 39 | 0.700 |
Why?
| | Liver | 2 | 2011 | 213 | 0.700 |
Why?
| | Epigenomics | 1 | 2015 | 14 | 0.550 |
Why?
| | Epigenesis, Genetic | 2 | 2015 | 91 | 0.540 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2014 | 72 | 0.540 |
Why?
| | CpG Islands | 1 | 2015 | 53 | 0.540 |
Why?
| | Neoplasms | 2 | 2008 | 280 | 0.530 |
Why?
| | Adenocarcinoma | 2 | 2013 | 231 | 0.530 |
Why?
| | Pancreatic Neoplasms | 2 | 2013 | 176 | 0.520 |
Why?
| | Toxicity Tests | 2 | 2011 | 9 | 0.510 |
Why?
| | Systems Biology | 2 | 2010 | 10 | 0.500 |
Why?
| | Ultrasonography, Mammary | 4 | 2022 | 15 | 0.490 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2013 | 19 | 0.490 |
Why?
| | Algorithms | 4 | 2019 | 428 | 0.430 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 128 | 0.420 |
Why?
| | Toluene | 1 | 2011 | 1 | 0.410 |
Why?
| | Environmental Pollutants | 1 | 2011 | 4 | 0.410 |
Why?
| | Transcriptome | 3 | 2015 | 90 | 0.350 |
Why?
| | Radiation Tolerance | 1 | 2008 | 8 | 0.350 |
Why?
| | Tumor Burden | 1 | 2008 | 38 | 0.340 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2008 | 81 | 0.340 |
Why?
| | Health Services Research | 1 | 2008 | 44 | 0.340 |
Why?
| | Female | 16 | 2022 | 18423 | 0.260 |
Why?
| | Sensitivity and Specificity | 4 | 2022 | 592 | 0.250 |
Why?
| | Gene Expression Profiling | 3 | 2015 | 182 | 0.240 |
Why?
| | Lymphatic Metastasis | 2 | 2022 | 101 | 0.230 |
Why?
| | Elasticity Imaging Techniques | 1 | 2020 | 10 | 0.200 |
Why?
| | Prognosis | 2 | 2015 | 1011 | 0.200 |
Why?
| | Humans | 19 | 2022 | 32988 | 0.200 |
Why?
| | Lipid Metabolism | 2 | 2011 | 47 | 0.200 |
Why?
| | Reproducibility of Results | 3 | 2015 | 893 | 0.190 |
Why?
| | Rats, Sprague-Dawley | 2 | 2011 | 484 | 0.180 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 83 | 0.180 |
Why?
| | Aged | 10 | 2020 | 10542 | 0.170 |
Why?
| | Rats | 2 | 2011 | 972 | 0.170 |
Why?
| | Middle Aged | 10 | 2020 | 11219 | 0.170 |
Why?
| | Case-Control Studies | 3 | 2016 | 694 | 0.170 |
Why?
| | Aged, 80 and over | 6 | 2020 | 5249 | 0.160 |
Why?
| | Selenium-Binding Proteins | 1 | 2016 | 2 | 0.150 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2016 | 7 | 0.150 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2016 | 4 | 0.150 |
Why?
| | Infertility, Female | 1 | 2016 | 23 | 0.150 |
Why?
| | Endometriosis | 1 | 2016 | 18 | 0.150 |
Why?
| | Osteolysis | 1 | 2018 | 154 | 0.150 |
Why?
| | Adult | 8 | 2020 | 9848 | 0.150 |
Why?
| | Signal Transduction | 2 | 2010 | 590 | 0.150 |
Why?
| | Interleukins | 1 | 2016 | 43 | 0.140 |
Why?
| | Lipoprotein(a) | 1 | 2016 | 10 | 0.140 |
Why?
| | Autoantibodies | 1 | 2016 | 119 | 0.140 |
Why?
| | Back Pain | 1 | 2016 | 63 | 0.140 |
Why?
| | Dyslipidemias | 1 | 2016 | 28 | 0.140 |
Why?
| | Time Factors | 2 | 2011 | 1873 | 0.140 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 80 | 0.140 |
Why?
| | Databases, Genetic | 1 | 2015 | 12 | 0.140 |
Why?
| | Cluster Analysis | 1 | 2015 | 60 | 0.140 |
Why?
| | Pericardium | 1 | 2015 | 30 | 0.130 |
Why?
| | Arteries | 1 | 2015 | 24 | 0.130 |
Why?
| | Heterozygote | 1 | 2015 | 115 | 0.130 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 120 | 0.130 |
Why?
| | Thyroid Diseases | 1 | 2015 | 22 | 0.130 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2015 | 118 | 0.130 |
Why?
| | Ataxia | 1 | 2015 | 80 | 0.130 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 63 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 126 | 0.130 |
Why?
| | Heart Atria | 1 | 2015 | 97 | 0.130 |
Why?
| | Postural Balance | 1 | 2015 | 130 | 0.130 |
Why?
| | Adipose Tissue | 1 | 2015 | 99 | 0.130 |
Why?
| | Computer Communication Networks | 1 | 2014 | 5 | 0.130 |
Why?
| | Prospective Studies | 4 | 2022 | 2002 | 0.130 |
Why?
| | Tremor | 1 | 2015 | 145 | 0.120 |
Why?
| | Echocardiography | 1 | 2015 | 207 | 0.120 |
Why?
| | Young Adult | 5 | 2020 | 2287 | 0.120 |
Why?
| | Intervertebral Disc | 1 | 2016 | 237 | 0.120 |
Why?
| | Area Under Curve | 1 | 2013 | 77 | 0.120 |
Why?
| | Heart Ventricles | 1 | 2015 | 225 | 0.120 |
Why?
| | Microarray Analysis | 2 | 2015 | 12 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 320 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 178 | 0.120 |
Why?
| | Iodide Peroxidase | 1 | 2015 | 145 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 173 | 0.110 |
Why?
| | Guanine | 1 | 2012 | 12 | 0.110 |
Why?
| | Glutamates | 1 | 2012 | 18 | 0.110 |
Why?
| | Fragile X Syndrome | 1 | 2015 | 189 | 0.110 |
Why?
| | Nervous System Diseases | 1 | 2015 | 159 | 0.110 |
Why?
| | T-Lymphocyte Subsets | 1 | 2012 | 88 | 0.110 |
Why?
| | Neoplasm Staging | 1 | 2013 | 457 | 0.110 |
Why?
| | Killer Cells, Natural | 1 | 2012 | 93 | 0.110 |
Why?
| | Disease Progression | 1 | 2015 | 870 | 0.110 |
Why?
| | Male | 8 | 2018 | 17726 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2013 | 2053 | 0.100 |
Why?
| | Inactivation, Metabolic | 1 | 2010 | 1 | 0.100 |
Why?
| | Trinitrotoluene | 1 | 2010 | 1 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 179 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 446 | 0.100 |
Why?
| | Hepatocytes | 1 | 2010 | 12 | 0.100 |
Why?
| | Artificial Intelligence | 2 | 2008 | 26 | 0.100 |
Why?
| | Cell Cycle | 1 | 2010 | 47 | 0.100 |
Why?
| | Animals | 2 | 2011 | 5371 | 0.100 |
Why?
| | Cell Death | 1 | 2010 | 68 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 378 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 494 | 0.090 |
Why?
| | Cell Proliferation | 1 | 2010 | 232 | 0.090 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2018 | 889 | 0.090 |
Why?
| | Poisson Distribution | 1 | 2008 | 26 | 0.090 |
Why?
| | Protein Conformation | 1 | 2008 | 87 | 0.080 |
Why?
| | Genome, Human | 1 | 2008 | 55 | 0.080 |
Why?
| | Cushing Syndrome | 1 | 2008 | 3 | 0.080 |
Why?
| | Bacteria | 1 | 2008 | 82 | 0.080 |
Why?
| | Protein Structure, Secondary | 1 | 2008 | 24 | 0.080 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 81 | 0.080 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2008 | 13 | 0.080 |
Why?
| | Forecasting | 1 | 2008 | 136 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2008 | 220 | 0.070 |
Why?
| | Models, Biological | 1 | 2008 | 397 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2020 | 3835 | 0.060 |
Why?
| | Gene Expression | 2 | 2016 | 267 | 0.060 |
Why?
| | China | 2 | 2015 | 62 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2019 | 84 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 462 | 0.040 |
Why?
| | Ultrasonography | 1 | 2020 | 215 | 0.040 |
Why?
| | Adolescent | 2 | 2016 | 2687 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2019 | 282 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 626 | 0.040 |
Why?
| | ROC Curve | 1 | 2016 | 155 | 0.040 |
Why?
| | Interleukin-7 | 1 | 2016 | 21 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2016 | 41 | 0.040 |
Why?
| | Georgia | 1 | 2016 | 16 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 56 | 0.040 |
Why?
| | Interleukin-10 | 1 | 2016 | 43 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 148 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2016 | 46 | 0.040 |
Why?
| | Radiography | 1 | 2018 | 717 | 0.040 |
Why?
| | Computers | 1 | 2015 | 28 | 0.040 |
Why?
| | Trinucleotide Repeat Expansion | 1 | 2015 | 48 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2015 | 75 | 0.030 |
Why?
| | Reaction Time | 1 | 2015 | 128 | 0.030 |
Why?
| | Alanine | 1 | 2015 | 17 | 0.030 |
Why?
| | Threonine | 1 | 2015 | 14 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 49 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 104 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2015 | 39 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 58 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 83 | 0.030 |
Why?
| | Regression Analysis | 1 | 2015 | 326 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 101 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 225 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2015 | 95 | 0.030 |
Why?
| | Reference Values | 1 | 2015 | 250 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2015 | 141 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2014 | 25 | 0.030 |
Why?
| | Sex Factors | 1 | 2016 | 548 | 0.030 |
Why?
| | Prevalence | 1 | 2016 | 554 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2014 | 49 | 0.030 |
Why?
| | Cohort Studies | 1 | 2019 | 2077 | 0.030 |
Why?
| | Software | 1 | 2014 | 77 | 0.030 |
Why?
| | Pilot Projects | 1 | 2015 | 466 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2015 | 726 | 0.030 |
Why?
| | B7 Antigens | 1 | 2012 | 1 | 0.030 |
Why?
| | Cerebral Cortex | 1 | 2015 | 206 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2012 | 38 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2012 | 33 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 350 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2012 | 36 | 0.030 |
Why?
| | Transcription Factors | 1 | 2014 | 176 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2012 | 20 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2012 | 27 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2012 | 66 | 0.030 |
Why?
| | Internet | 1 | 2014 | 112 | 0.030 |
Why?
| | Immunologic Memory | 1 | 2012 | 37 | 0.030 |
Why?
| | Chicago | 1 | 2016 | 957 | 0.030 |
Why?
| | Risk Assessment | 1 | 2016 | 814 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2012 | 119 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 1058 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2015 | 515 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2012 | 97 | 0.030 |
Why?
| | Survival Analysis | 1 | 2012 | 372 | 0.030 |
Why?
| | Risk Factors | 1 | 2016 | 2762 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2008 | 10 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2008 | 56 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2008 | 471 | 0.020 |
Why?
| | Logistic Models | 1 | 2008 | 474 | 0.020 |
Why?
|
|
Deng's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|